Cargando…

A novel and well tolerated mite allergoid subcutaneous immunotherapy: evidence of clinical and immunologic efficacy

Allergy to house dust mite is one of the most common causes of allergic rhinitis. A novel tyrosine-adsorbed, modified allergen product, Acarovac Plus, developed for the treatment of perennial mite allergy seeks to address the underlying cause of allergic rhinitis in this instance. One of two dosing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roger, Albert, Depreux, Nathalie, Jurgens, Yani, Heath, Matthew D, Garcia, Gloria, Skinner, Murray A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4217550/ https://www.ncbi.nlm.nih.gov/pubmed/25400929 http://dx.doi.org/10.1002/iid3.23

Ejemplares similares

First‐in‐human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy
por: Nieto, Antonio, et al.
Publicado: (2022)

Twenty years’ observation of subcutaneous pollen allergoid immunotherapy efficacy in adults
por: Bożek, Andrzej, et al.
Publicado: (2017)

Transcriptome analysis and safety profile of the early-phase clinical response to an adjuvanted grass allergoid immunotherapy
por: Starchenka, Sviatlana, et al.
Publicado: (2019)

11 Efficacy and Tolerability of HDM Injective Immunotherapy With Monomeric Allergoid
por: Compalati, Enrico, et al.
Publicado: (2012)

Peripheral effector memory regulatory T cells are incremented and functionally enhanced in successful mite monomeric allergoid sublingual immunotherapy
por: Petrarca, Claudia, et al.
Publicado: (2020)

484 Allergen Standardisation in Allergens and Allergoids—Challenges and Considerations
por: Skinner, Murray, et al.
Publicado: (2012)

Real-Life Effectiveness of Subcutaneous Immune Therapy with Carbamylated Monomeric Allergoids on Mite, Grass, and Pellitory Respiratory Allergy: A Retrospective Study
por: Di Gioacchino, Mario, et al.
Publicado: (2022)

Safety of injective immunotherapy with monomeric carbamylated allergoid given to pediatric patients with allergic rhinitis with/without asthma due to house dust mite
por: Compalati, Enrico, et al.
Publicado: (2015)

Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy
por: Worm, M., et al.
Publicado: (2018)

Immunologic changes after house dust mite modified rush subcutaneous immunotherapy in allergic rhinitis children
por: Rattanamanee, Tipyapa, et al.
Publicado: (2022)

Effects of house dust mite subcutaneous immunotherapy in real-life. Immunological and clinical biomarkers and economic impact analysis
por: Caruso, Cristiano, et al.
Publicado: (2023)

Allergen-Specific Immunotherapy with Monomeric Allergoid in a Mouse Model of Atopic Dermatitis
por: Shershakova, Nadezda, et al.
Publicado: (2015)

Specific immunotherapy with mugwort pollen allergoid reduce bradykinin release into the nasal fluid
por: Gawlik, Radoslaw, et al.
Publicado: (2016)

SCIT with a high-dose house dust mite allergoid is well tolerated: safety data from pooled clinical trials and more than 10 years of daily practice analyzed in different subgroups
por: Klimek, Ludger, et al.
Publicado: (2018)

Immunological parameters as biomarkers of response to MicroCrystalline Tyrosine-adjuvanted mite immunotherapy()
por: Justicia, José L., et al.
Publicado: (2021)

Molecular fingerprinting of complex grass allergoids: size assessments reveal new insights in epitope repertoires and functional capacities
por: Starchenka, S., et al.
Publicado: (2017)

Subcutaneous Immunotherapy (SCIT) with the New Polymerized Molecular Allergoid Alt a1: A Pilot Study in Children with Allergic Rhinitis Sensitized to Alternaria Alternata
por: Brindisi, Giulia, et al.
Publicado: (2023)

The relative clinical impact of sublingual immunotherapy with carbamylated monomeric allergoids on allergic respiratory symptoms
por: Compalati, Enrico, et al.
Publicado: (2015)

A non-stationary Markov model for economic evaluation of grass pollen allergoid immunotherapy
por: Bilancia, Massimo, et al.
Publicado: (2020)

Intradermal Phleum pratense allergoid immunotherapy. Double‐blind, randomized, placebo‐controlled trial
por: Sola Martínez, Francisco Javier, et al.
Publicado: (2020)

An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial
por: Chaker, A. M., et al.
Publicado: (2016)

A 12‐week DBPC dose‐finding study with sublingual monomeric allergoid tablets in house dust mite‐allergic patients
por: Hüser, C., et al.
Publicado: (2016)

A novel peanut allergoid is safe and effective in immunotherapy in a peanut allergy mouse model
por: Smit, J, et al.
Publicado: (2013)

T-cell subset changes during the first year of pre-seasonal allergoid allergen-specific immunotherapy
por: Reithofer, Manuel, et al.
Publicado: (2023)

Open-label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patients
por: Rieker-Schwienbacher, Juliane, et al.
Publicado: (2013)

Efficacy and safety of birch pollen allergoid subcutaneous immunotherapy: A 2‐year double‐blind, placebo‐controlled, randomized trial plus 1‐year open‐label extension
por: Worm, Margitta, et al.
Publicado: (2019)

Tolerability of an Immunologically Enhanced Subcutaneous Immunotherapy Preparation in Patients Treated with Concomitant Allergy Immunotherapy: A Non-Interventional Observational Study
por: Reiber, Rainer, et al.
Publicado: (2017)

Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany
por: Verheggen, Bram G, et al.
Publicado: (2015)

Safety of house dust mite subcutaneous immunotherapy in preschool children with respiratory allergic diseases
por: Yang, Yaqi, et al.
Publicado: (2021)

House Dust Mite Subcutaneous Immunotherapy and Lung Function Trajectory in Children and Adolescents with Asthma
por: Nogami, Kazutaka, et al.
Publicado: (2022)

Dropouts From Sublingual Immunotherapy and the Transition to Subcutaneous Immunotherapy in House Dust Mite-Sensitized Allergic Rhinitis Patients
por: Chen, Huan, et al.
Publicado: (2022)

Murine subcutaneous immunotherapy models with beneficial immunological and physiological effects
por: Chang, Yoon-Seok, et al.
Publicado: (2013)

Effectiveness and safety of a microcrystalline tyrosine‐adjuvanted Dermatophagoides pteronyssinus allergoid immunotherapy in adult patients with allergic asthma and rhinitis: A real‐life prospective observational study
por: Padró, Clara, et al.
Publicado: (2022)

Evaluation of safety and tolerability of a rush up-dosing allergen-specific immunotherapy with grass pollen, birch, hazel, and alder allergoid in children with allergic rhinoconjunctivitis, with or without asthma
por: Traina, Giovanni Maria, et al.
Publicado: (2021)

98 Specific IGE and IGG Binding to Allergoids of Phleum pratense
por: Cases, Barbara, et al.
Publicado: (2012)

Novel vaccines targeting dendritic cells by coupling allergoids to mannan
por: Benito-Villalvilla, Cristina, et al.
Publicado: (2018)

Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial
por: Corren, Jonathan, et al.
Publicado: (2021)

Systemic Reactions to Dust Mite Subcutaneous Immunotherapy: A 3-Year Follow-up Study
por: Dong, Xiang, et al.
Publicado: (2016)

Metabolomics Reveals Process of Allergic Rhinitis Patients with Single- and Double-Species Mite Subcutaneous Immunotherapy
por: Zheng, Peiyan, et al.
Publicado: (2021)

Allergen-specific subcutaneous immunotherapy in allergic asthma: immunologic mechanisms and improvement
por: Taher, Yousef A., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_a15fkbn17cev3mbu9gv6hag5j8